enGene Holdings Inc. (NASDAQ:ENGN) Major Shareholder Growth Opportunities F. Forbion Acquires 10,153 Shares of Stock

enGene Holdings Inc. (NASDAQ:ENGN) major shareholder Growth Opportunities F. Forbion bought 10,153 shares of the business’s stock in a transaction on Wednesday, October 2nd. The shares were acquired at an average price of $6.37 per share, with a total value of $64,674.61. Following the transaction, the insider now directly owns 2,446,223 shares of the company’s stock, valued at approximately $15,582,440.51. This trade represents a 0.00 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Large shareholders that own at least 10% of a company’s shares are required to disclose their transactions with the SEC.

enGene Price Performance

Shares of NASDAQ:ENGN opened at $9.02 on Friday. The company has a 50 day moving average of $6.71 and a 200 day moving average of $9.78. The company has a current ratio of 19.52, a quick ratio of 19.52 and a debt-to-equity ratio of 0.09. The stock has a market cap of $398.38 million, a P/E ratio of -5.24 and a beta of -0.69. enGene Holdings Inc. has a 12 month low of $4.42 and a 12 month high of $43.00.

enGene (NASDAQ:ENGN) last released its quarterly earnings results on Tuesday, September 10th. The company reported ($0.32) EPS for the quarter, beating analysts’ consensus estimates of ($0.37) by $0.05. As a group, sell-side analysts forecast that enGene Holdings Inc. will post -1.56 EPS for the current fiscal year.

Hedge Funds Weigh In On enGene

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Janus Henderson Group PLC purchased a new stake in shares of enGene in the 1st quarter valued at about $17,095,000. SR One Capital Management LP bought a new position in shares of enGene in the second quarter worth approximately $4,715,000. Logos Global Management LP raised its stake in enGene by 50.0% in the second quarter. Logos Global Management LP now owns 1,200,000 shares of the company’s stock valued at $11,316,000 after purchasing an additional 400,000 shares in the last quarter. Finally, Altitude Crest Partners Inc. bought a new stake in enGene during the first quarter valued at approximately $2,039,000. 64.16% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

ENGN has been the topic of a number of recent research reports. Morgan Stanley restated an “overweight” rating and set a $40.00 price target on shares of enGene in a research note on Wednesday, September 11th. Oppenheimer restated an “outperform” rating and set a $30.00 target price on shares of enGene in a research report on Tuesday, September 24th. Seven analysts have rated the stock with a buy rating, According to data from MarketBeat.com, enGene has a consensus rating of “Buy” and an average target price of $33.67.

enGene Company Profile

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin.